TeleClinic review

TeleClinic clears the disclosure bars that matter. It names its pharmacy — Rush Pharmacy, quoted directly on its own pharmacy-partners page as a licensed 503A compounder — publishes an explicit 47-state availability list including which three states it excludes, and holds a LegitScript certificate whose seal resolves. On its GLP-1 line it also publishes the ongoing rate beside the introductory one, which is exactly right. Its NAD⁺ page does not do the same: it shows $99 for a first month against a $129 regular price and $250 for three months, and states no ongoing month-to-month rate at all, so you can't tell what NAD⁺ costs after the first month.

TeleClinic (Teleclinic Holdings LLC) is a cash-pay telehealth platform selling compounded semaglutide and tirzepatide alongside two non-GLP-1 injectables: an NAD⁺ injection and a B12 with MIC lipotropic. Prescriptions are filled by Rush Pharmacy, which TeleClinic describes as a PCAB-accredited 503A compounding pharmacy — TeleClinic's claim, which you can check on PCAB's public accreditation lookup. It operates in 47 states, excluding California, South Carolina and New Jersey, with free shipping and no insurance accepted.

Asynchronous, cash-pay and unusually well documented for a platform this size. The pharmacy disclosure is quoted verbatim on a dedicated pharmacy-partners page — all prescriptions filled by Rush Pharmacy, a licensed 503A compounding pharmacy authorized under Section 503A — which is a specific, checkable statement rather than a reference to "a US-licensed pharmacy". The state list is explicit and names the exclusions, which is far more useful than a nationwide claim, and the LegitScript seal resolves to a real certificate image rather than a decorative badge. The NAD⁺ product itself is described with a frequency choice — twice weekly to start, three times weekly, or daily — with dosing stated as selected by your provider, though no mg strength is published. Two things to weigh. The PCAB accreditation claim is TeleClinic's, not an independent finding, so treat it as a claim. And its billing structure leans on quarterly commitments across the board: its GLP-1 intro rates are stated as billed quarterly, and its NAD⁺ page offers a three-month option beside a first-month one without ever describing the steady state.

Clearer on its GLP-1 line than on NAD⁺, which is an unusual failure mode. For semaglutide and tirzepatide the site publishes both halves — $139 and $219 a month for the first quarter, billed quarterly, then $199 and $299 ongoing month to month — so a reader can see the real cost of month four. Its NAD⁺ page does not. It reads "1 Month $99 $129" and "3 Months $250 $319", with "$99 billed monthly" beside the frequency selector, and never states what the month-to-month rate becomes once the introductory period ends. A struck-through $129 is a regular-price anchor, not a published ongoing rate, and $250 for three months works out to about $83 a month, which does not reconcile with either figure. Given that the same company publishes its ongoing GLP-1 rates plainly, the silence on NAD⁺ stands out. Ask what month four costs before you buy month one. Its B12 with MIC lipotropic is listed at $109 for a first month, with a quarterly rate around $84 a month.

Compounded; not FDA-approved — disclosed by the site itself. Prescription required only if a licensed provider finds it appropriate. Naming the dispensing pharmacy is the single most useful disclosure for an injectable and TeleClinic makes it; compounded sterile products are still not reviewed by the FDA for purity and potency the way approved drugs are, and the PCAB accreditation attached to the pharmacy is TeleClinic's own description, so ask the pharmacy to confirm it. On the evidence, the NAD⁺ injection sits at the weak end of the category. There are no controlled human outcome trials for injected NAD⁺ at all; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears plasma quickly, which tells you about disposal rather than about benefit. The NAD⁺ forms with human trial data are the oral precursors nicotinamide riboside and nicotinamide mononucleotide, and what those trials reliably demonstrate is a raised blood NAD⁺ level — a biomarker, not a demonstrated clinical benefit. The site's frequency ladder, from twice weekly up to daily, is a dosing convention rather than something derived from outcome data, and no mg strength is published for any tier. Individual results vary.